Chapter 18 Changes in the Endocannabinoid System May Give Insight into new and Effective Treatments for Cancer

Vitamins and Hormones

Volumn 81, Issue C, 2009, Pages 469-485

  Alpini, Gianfranco ^a,c   DeMorrow, Sharon ^a,b  

^a TEXAS A AND M HEALTH SCIENCE CENTER   (United States)

^b SCOTT AND WHITE MEMORIAL HOSPITAL   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIDASE; AMIDE; ANANDAMIDE; ANTINEOPLASTIC AGENT; ARACHIDONIC ACID DERIVATIVE; CANNABINOID RECEPTOR; CARCINOGEN; ENDOCANNABINOID; ENZYME INHIBITOR; FATTY ACID AMIDASE; FATTY-ACID AMIDE HYDROLASE;

ANIMAL; CANCER INVASION; CELL DIVISION; CELL MOTION; DRUG ANTAGONISM; DRUG EFFECT; DRUG POTENTIATION; HUMAN; METASTASIS; NEOPLASM; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; REVIEW;

AMIDOHYDROLASES; ANIMALS; ANTINEOPLASTIC AGENTS; ARACHIDONIC ACIDS; CARCINOGENS; CELL DIVISION; CELL MOVEMENT; ENDOCANNABINOIDS; ENZYME INHIBITORS; HUMANS; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; POLYUNSATURATED ALKAMIDES; RECEPTORS, CANNABINOID;

EID: 67651151092     PISSN: 00836729     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S0083-6729(09)81018-2     Document Type: Review

References (64)

1. Alberich Jorda M., Rayman N., Tas M., Verbakel S.E., Battista N., van Lom K., Lowenberg B., Maccarrone M., and Delwel R. The peripheral cannabinoid receptor Cb2, frequently expressed on AML blasts, either induces a neutrophilic differentiation block or confers abnormal migration properties in a ligand-dependent manner. Blood 104 (2004) 526-534
2. Baker D., Pryce G., Croxford J.L., Brown P., Pertwee R.G., Huffman J.W., and Layward L. Cannabinoids control spasticity and tremor in a multiple sclerosis model. Nature 404 (2000) 84-87
3. Bifulco M., Laezza C., Valenti M., Ligresti A., Portella G., and Di Marzo V. A new strategy to block tumor growth by inhibiting endocannabinoid inactivation. FASEB J. 18 (2004) 1606-1608
4. Bisogno T., Ligresti A., and Di Marzo V. The endocannabinoid signalling system: Biochemical aspects. Pharmacol. Biochem. Behav. 81 (2005) 224-238
5. Blazquez C., Carracedo A., Salazar M., Lorente M., Egia A., Gonzalez-Feria L., Haro A., Velasco G., and Guzman M. Down-regulation of tissue inhibitor of metalloproteinases-1 in gliomas: A new marker of cannabinoid antitumoral activity?. Neuropharmacology 54 (2008) 235-243
6. Blazquez C., Salazar M., Carracedo A., Lorente M., Egia A., Gonzalez-Feria L., Haro A., Velasco G., and Guzman M. Cannabinoids inhibit glioma cell invasion by down-regulating matrix metalloproteinase-2 expression. Cancer Res. 68 (2008) 1945-1952
7. Caffarel M.M., Sarrio D., Palacios J., Guzman M., and Sanchez C. Delta9-tetrahydrocannabinol inhibits cell cycle progression in human breast cancer cells through Cdc2 regulation. Cancer Res. 66 (2006) 6615-6621
8. Calignano A., La Rana G., Giuffrida A., and Piomelli D. Control of pain initiation by endogenous cannabinoids. Nature 394 (1998) 277-281
9. Chan V.Y., Chan M.W., Leung W.K., Leung P.S., Sung J.J., and Chan F.K. Intestinal trefoil factor promotes invasion in non-tumorigenic Rat-2 fibroblast cell. Regul. Pept. 127 (2005) 87-94
10. Contassot E., Tenan M., Schnuriger V., Pelte M.F., and Dietrich P.Y. Arachidonyl ethanolamide induces apoptosis of uterine cervix cancer cells via aberrantly expressed vanilloid receptor-1. Gynecol. Oncol. 93 (2004) 182-188
11. Contassot E., Wilmotte R., Tenan M., Belkouch M.C., Schnuriger V., de Tribolet N., Burkhardt K., and Dietrich P.Y. Arachidonylethanolamide induces apoptosis of human glioma cells through vanilloid receptor-1. J. Neuropathol. Exp. Neurol. 63 (2004) 956-963
12. Curran S., and Murray G.I. Matrix metalloproteinases: Molecular aspects of their roles in tumour invasion and metastasis. Eur. J. Cancer 36 (2000) 1621-1630
13. DeMorrow S., Glaser S., Francis H., Venter J., Vaculin B., Vaculin S., and Alpini G. Opposing actions of endocannabinoids on cholangiocarcinoma growth: Recruitment of Fas and Fas ligand to lipid rafts. J. Biol. Chem. 282 (2007) 13098-13113
14. DeMorrow S., Francis H., Gaudio E., Venter J., Franchitto A., Kopriva S., Onori P., Mancinelli R., Frampton G., Coufal M., Mitchell B., Vaculin B., and Alpini G. The endocannabinoid anandamide inhibits cholangiocarcinoma growth via activation of the noncanonical Wnt signaling pathway. Am. J. Physiol. Gastrointest Liver Physiol. 295 (2008) G1150-G1158
15. De Petrocellis L., Melck D., Palmisano A., Bisogno T., Laezza C., Bifulco M., and Di Marzo V. The endogenous cannabinoid anandamide inhibits human breast cancer cell proliferation. Proc. Natl. Acad. Sci. USA 95 (1998) 8375-8380
16. Devane W.A., Dysarz III F.A., Johnson M.R., Melvin L.S., and Howlett A.C. Determination and characterization of a cannabinoid receptor in rat brain. Mol. Pharmacol. 34 (1988) 605-613
17. Di Marzo V., and Deutsch D.G. Biochemistry of the endogenous ligands of cannabinoid receptors. Neurobiol. Dis. 5 (1998) 386-404
18. Di Marzo V., Melck D., Orlando P., Bisogno T., Zagoory O., Bifulco M., Vogel Z., and De Petrocellis L. Palmitoylethanolamide inhibits the expression of fatty acid amide hydrolase and enhances the anti-proliferative effect of anandamide in human breast cancer cells. Biochem. J. 358 (2001) 249-255
19. Ek S., Hogerkorp C.M., Dictor M., Ehinger M., and Borrebaeck C.A. Mantle cell lymphomas express a distinct genetic signature affecting lymphocyte trafficking and growth regulation as compared with subpopulations of normal human B cells. Cancer Res. 62 (2002) 4398-4405
20. Ferrara N. VEGF as a therapeutic target in cancer. Oncology 69 Suppl. 3 (2005) 11-16
21. Ferrara N., and Kerbel R.S. Angiogenesis as a therapeutic target. Nature 438 (2005) 967-974
22. Fidler I.J. Critical determinants of metastasis. Semin. Cancer Biol. 12 (2002) 89-96
23. Galve-Roperh I., Sanchez C., Cortes M.L., del Pulgar T.G., Izquierdo M., and Guzman M. Anti-tumoral action of cannabinoids: Involvement of sustained ceramide accumulation and extracellular signal-regulated kinase activation. Nat. Med. 6 (2000) 313-319
24. Glaser S.T., Kaczocha M., and Deutsch D.G. Anandamide transport: A critical review. Life Sci. 77 (2005) 1584-1604
25. Grimaldi C., Pisanti S., Laezza C., Malfitano A.M., Santoro A., Vitale M., Caruso M.G., Notarnicola M., Iacuzzo I., Portella G., Di Marzo V., and Bifulco M. Anandamide inhibits adhesion and migration of breast cancer cells. Exp. Cell Res. 312 (2006) 363-373
26. Hart S., Fischer O.M., and Ullrich A. Cannabinoids induce cancer cell proliferation via tumor necrosis factor alpha-converting enzyme (TACE/ADAM17)-mediated transactivation of the epidermal growth factor receptor. Cancer Res. 64 (2004) 1943-1950
27. Hinz B., Ramer R., Eichele K., Weinzierl U., and Brune K. R(+)-methanandamide-induced cyclooxygenase-2 expression in H4 human neuroglioma cells: Possible involvement of membrane lipid rafts. Biochem. Biophys. Res. Commun. 324 (2004) 621-626
28. Hinz B., Ramer R., Eichele K., Weinzierl U., and Brune K. Up-regulation of cyclooxygenase-2 expression is involved in R(+)-methanandamide-induced apoptotic death of human neuroglioma cells. Mol. Pharmacol. 66 (2004) 1643-1651
29. Hsu S.S., Huang C.J., Cheng H.H., Chou C.T., Lee H.Y., Wang J.L., Chen I.S., Liu S.I., Lu Y.C., Chang H.T., Huang J.K., Chen J.S., et al. Anandamide-induced Ca2+ elevation leading to p38 MAPK phosphorylation and subsequent cell death via apoptosis in human osteosarcoma cells. Toxicology 231 (2007) 21-29
30. Islam T.C., Asplund A.C., Lindvall J.M., Nygren L., Liden J., Kimby E., Christensson B., Smith C.I., and Sander B. High level of cannabinoid receptor 1, absence of regulator of G protein signalling 13 and differential expression of Cyclin D1 in mantle cell lymphoma. Leukemia 17 (2003) 1880-1890
31. Jacobsson S.O., Wallin T., and Fowler C.J. Inhibition of rat C6 glioma cell proliferation by endogenous and synthetic cannabinoids. Relative involvement of cannabinoid and vanilloid receptors. J. Pharmacol. Exp. Ther. 299 (2001) 951-959
32. Joseph J., Niggemann B., Zaenker K.S., and Entschladen F. Anandamide is an endogenous inhibitor for the migration of tumor cells and T lymphocytes. Cancer Immunol. Immunother. 53 (2004) 723-728
33. Khokha R., Waterhouse P., Yagel S., Lala P.K., Overall C.M., Norton G., and Denhardt D.T. Antisense RNA-induced reduction in murine TIMP levels confers oncogenicity on Swiss 3T3 cells. Science 243 (1989) 947-950
34. Laezza C., Pisanti S., Crescenzi E., and Bifulco M. Anandamide inhibits Cdk2 and activates Chk1 leading to cell cycle arrest in human breast cancer cells. FEBS Lett. 580 (2006) 6076-6082
35. Lambert S., Vind-Kezunovic D., Karvinen S., and Gniadecki R. Ligand-independent activation of the EGFR by lipid raft disruption. J. Invest. Dermatol. 126 (2006) 954-962
36. Ligresti A., Bisogno T., Matias I., De Petrocellis L., Cascio M.G., Cosenza V., D'Argenio G., Scaglione G., Bifulco M., Sorrentini I., and Di Marzo V. Possible endocannabinoid control of colorectal cancer growth. Gastroenterology 125 (2003) 677-687
37. Manzanares J., Corchero J., Romero J., Fernandez-Ruiz J.J., Ramos J.A., and Fuentes J.A. Pharmacological and biochemical interactions between opioids and cannabinoids. Trends Pharmacol. Sci. 20 (1999) 287-294
38. Mathay C., Giltaire S., Minner F., Bera E., Herin M., and Poumay Y. Heparin-binding EGF-like growth factor is induced by disruption of lipid rafts and oxidative stress in keratinocytes and participates in the epidermal response to cutaneous wounds. J. Invest. Dermatol. 128 (2008) 717-727
39. Matsuda L.A., Lolait S.J., Brownstein M.J., Young A.C., and Bonner T.I. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 346 (1990) 561-564
40. McKallip R.J., Lombard C., Fisher M., Martin B.R., Ryu S., Grant S., Nagarkatti P.S., and Nagarkatti M. Targeting CB2 cannabinoid receptors as a novel therapy to treat malignant lymphoblastic disease. Blood 100 (2002) 627-634
41. McKallip R.J., Nagarkatti M., and Nagarkatti P.S. Delta-9-tetrahydrocannabinol enhances breast cancer growth and metastasis by suppression of the antitumor immune response. J. Immunol. 174 (2005) 3281-3289
42. Melck D., Rueda D., Galve-Roperh I., De Petrocellis L., Guzman M., and Di Marzo V. Involvement of the cAMP/protein kinase A pathway and of mitogen-activated protein kinase in the anti-proliferative effects of anandamide in human breast cancer cells. FEBS Lett. 463 (1999) 235-240
43. Melck D., De Petrocellis L., Orlando P., Bisogno T., Laezza C., Bifulco M., and Di Marzo V. Suppression of nerve growth factor Trk receptors and prolactin receptors by endocannabinoids leads to inhibition of human breast and prostate cancer cell proliferation. Endocrinology 141 (2000) 118-126
44. Mimeault M., Pommery N., Wattez N., Bailly C., and Henichart J.P. Anti-proliferative and apoptotic effects of anandamide in human prostatic cancer cell lines: Implication of epidermal growth factor receptor down-regulation and ceramide production. Prostate 56 (2003) 1-12
45. Munro S., Thomas K.L., and Abu-Shaar M. Molecular characterization of a peripheral receptor for cannabinoids. Nature 365 (1993) 61-65
46. Pagotto U., Marsicano G., Fezza F., Theodoropoulou M., Grubler Y., Stalla J., Arzberger T., Milone A., Losa M., Di Marzo V., Lutz B., and Stalla G.K. Normal human pituitary gland and pituitary adenomas express cannabinoid receptor type 1 and synthesize endogenous cannabinoids: First evidence for a direct role of cannabinoids on hormone modulation at the human pituitary level. J. Clin. Endocrinol. Metab. 86 (2001) 2687-2696
47. Patsos H.A., Hicks D.J., Dobson R.R., Greenhough A., Woodman N., Lane J.D., Williams A.C., and Paraskeva C. The endogenous cannabinoid, anandamide, induces cell death in colorectal carcinoma cells: A possible role for cyclooxygenase 2. Gut 54 (2005) 1741-1750
48. Petersen G., Moesgaard B., Schmid P.C., Schmid H.H., Broholm H., Kosteljanetz M., and Hansen H.S. Endocannabinoid metabolism in human glioblastomas and meningiomas compared to human non-tumour brain tissue. J. Neurochem. 93 (2005) 299-309
49. Piomelli D., Giuffrida A., Calignano A., and Rodriguez de Fonseca F. The endocannabinoid system as a target for therapeutic drugs. Trends Pharmacol. Sci. 21 (2000) 218-224
50. Pisanti S., Borselli C., Oliviero O., Laezza C., Gazzerro P., and Bifulco M. Antiangiogenic activity of the endocannabinoid anandamide: Correlation to its tumor-suppressor efficacy. J. Cell Physiol. 211 (2007) 495-503
51. Ramer R., and Hinz B. Inhibition of cancer cell invasion by cannabinoids via increased expression of tissue inhibitor of matrix metalloproteinases-1. J. Natl. Cancer Inst. 100 (2008) 59-69
52. Ramer R., Brune K., Pahl A., and Hinz B. R(+)-methanandamide induces cyclooxygenase-2 expression in human neuroglioma cells via a non-cannabinoid receptor-mediated mechanism. Biochem. Biophys. Res. Commun. 286 (2001) 1144-1152
53. Ruiz L., Miguel A., and Diaz-Laviada I. Delta9-tetrahydrocannabinol induces apoptosis in human prostate PC-3 cells via a receptor-independent mechanism. FEBS Lett. 458 (1999) 400-404
54. Ryberg E., Larsson N., Sjogren S., Hjorth S., Hermansson N.O., Leonova J., Elebring T., Nilsson K., Drmota T., and Greasley P.J. The orphan receptor GPR55 is a novel cannabinoid receptor. Br. J. Pharmacol. 152 (2007) 1092-1101
55. Sanchez C., Galve-Roperh I., Canova C., Brachet P., and Guzman M. Delta9-tetrahydrocannabinol induces apoptosis in C6 glioma cells. FEBS Lett. 436 (1998) 6-10
56. Sanchez C., de Ceballos M.L., del Pulgar T.G., Rueda D., Corbacho C., Velasco G., Galve-Roperh I., Huffman J.W., Ramon y Cajal S., and Guzman M. Inhibition of glioma growth in vivo by selective activation of the CB(2) cannabinoid receptor. Cancer Res. 61 (2001) 5784-5789
57. Sanchez M.G., Sanchez A.M., Ruiz-Llorente L., and Diaz-Laviada I. Enhancement of androgen receptor expression induced by (R)-methanandamide in prostate LNCaP cells. FEBS Lett. 555 (2003) 561-566
58. Sarfaraz S., Afaq F., Adhami V.M., and Mukhtar H. Cannabinoid receptor as a novel target for the treatment of prostate cancer. Cancer Res. 65 (2005) 1635-1641
59. Schmid P.C., Wold L.E., Krebsbach R.J., Berdyshev E.V., and Schmid H.H. Anandamide and other N-acylethanolamines in human tumors. Lipids 37 (2002) 907-912
60. Shi Y., Zou M., Baitei E.Y., Alzahrani A.S., Parhar R.S., Al-Makhalafi Z., and Al-Mohanna F.A. Cannabinoid 2 receptor induction by IL-12 and its potential as a therapeutic target for the treatment of anaplastic thyroid carcinoma. Cancer Gene Ther. 15 (2008) 101-107
61. Stamenkovic I. Matrix metalloproteinases in tumor invasion and metastasis. Semin. Cancer Biol. 10 (2000) 415-433
62. Takeda S., Yamaori S., Motoya E., Matsunaga T., Kimura T., Yamamoto I., and Watanabe K. Delta(9)-Tetrahydrocannabinol enhances MCF-7 cell proliferation via cannabinoid receptor-independent signaling. Toxicology 245 (2008) 141-146
63. Voth E.A., and Schwartz R.H. Medicinal applications of delta-9-tetrahydrocannabinol and marijuana. Ann. Intern. Med. 126 (1997) 791-798
64. Zacchigna S., Zentilin L., Morini M., Dell'Eva R., Noonan D.M., Albini A., and Giacca M. AAV-mediated gene transfer of tissue inhibitor of metalloproteinases-1 inhibits vascular tumor growth and angiogenesis in vivo. Cancer Gene Ther. 11 (2004) 73-80